Medical University of South Carolina NCORP Minority/Underserved Community Site

描述（由申请人提供）：南卡罗来纳医科大学/霍林斯癌症中心（MUSC/HCC），自2009年以来一直是国家癌症研究所（NCI）指定的癌症中心，长期以来一直是NCI合作小组的参与者，并且很好地定位于NCI社区肿瘤研究计划（NCORP）中领先的少数民族/服务不足的社区站点。最初是CALGB的主要成员（1985-2002），2002年MUSC/HCC成为SWOG的主要成员。随后几年，MUSC/HCC成为COG、RTOG、ACoSOG、ACRIN、NSABP的主要成员，同时也是GOG的附属成员。在最近的年度报告期内，所有这些NCI赞助的项目的累计收益总体增长显著，有134人入学，其中28%是少数民族/种族。MUSC/HCC及其合作站点——MUSC/HCC东库珀、MUSC/HCC北查尔斯顿、拉尔夫·h·约翰逊退伍军人管理医疗中心、MUSC/希尔顿海德乳房健康中心、乔治城卫生系统和自我区域医疗中心——为NCORP带来的主要资产是其明显的能力，可以覆盖少数民族/少数民族癌症人口（其集水区32%）和联邦政府指定的服务不足/农村癌症人口（其集水区43%）。MUSC/HCC为NCORP项目带来的另一项重要资产是其在癌症差异和癌症护理交付研究（CCDR）的开发和实施方面的专业知识和领导能力。MUSC/HCC研究人员在这些重点领域拥有强大的NCI投资组合和其他同行评审资助计划，去年招募了500多人，并准备与NCORP研究基地合作开发和实施更多的CCDR研究。最后，MUSC/HCC为其集中临床研究运作投入了大量资源。它能够管理大量的研究组合，并在过去十年中通过其外部审计一再证明高质量的合规性和数据。MUSC/HCC临床试验办公室将提供有效和高效的基础设施，以支持研究人员和临床医生在NCORP内实施临床试验和CCDR。

DESCRIPTION (provided by applicant): The Medical University of South Carolina/Hollings Cancer Center (MUSC/HCC), a National Cancer Institute (NCI)-designated cancer center since 2009, has been a long-standing NCI cooperative group participant and is well positioned to be a leading Minority/Underserved Community Site within the NCI's Community Oncology Research Program (NCORP). Originally a main member of CALGB (1985-2002), in 2002 MUSC/HCC became a main member of SWOG. In subsequent years, MUSC/HCC became a main member of COG, RTOG, ACoSOG, ACRIN, NSABP and is also an affiliate member of GOG. The overall growth in accrual across all of these NCI sponsored programs has been significant with 134 enrollments in the most recent annual reporting period, of which 28% were ethnic/racial minorities. A major asset that MUSC/HCC and its partnering sites - MUSC/HCC East Cooper, MUSC/HCC North Charleston, Ralph H. Johnson Veterans Administration Medical Center, MUSC/Hilton Head Breast Health Center, Georgetown Health System, and Self Regional Healthcare - bring to the NCORP is its demonstrable ability to reach an ethnic/minority cancer population (32% in its catchment area) and a federally designated underserved/rural cancer population (43% in its catchment area). Another major asset that MUSC/HCC brings to the NCORP program is its considerable expertise and leadership in the development and implementation of cancer disparities and cancer care delivery research (CCDR). MUSC/HCC investigators have a robust portfolio of NCI and other peer-reviewed funded initiatives in these focal areas, enrolling more than 500 individuals in the last year, and are poised to collaborate with NCORP research bases in the development and implementation of additional CCDR research. Finally, MUSC/HCC has invested considerable resources to its centralized clinical research operation. It is capable of managing a large portfolio of studies and has repeatedly demonstrated high quality compliance and data through its external audits during the past decade. The MUSC/HCC Clinical Trials Office will provide an effective and efficient infrastructure to support investigators and clinicians in implementing clinical trials and CCDR within the NCORP.